Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
octreotide + lanreotide
- Development stage
- Unknown
- Lead developer
- University of Naples Federico II
- Modality
- Peptides
- Administration
- Intramuscular, Subcutaneous
01
Overview
Octreotide-LAR + Lanreotide Autogel is a combination therapy involving two long-acting depot somatostatin analogues (SSAs) being evaluated for the treatment of advanced hepatocellular carcinoma (HCC). The combination is specifically studied in patients with liver cirrhosis whose tumors express somatostatin receptors (SSTRs). Octreotide-LAR (Sandostatin LAR) is a synthetic peptide analogue of somatostatin administered intramuscularly, while Lanreotide Autogel (Somatuline Depot) is a deep subcutaneous injection. Both drugs function as agonists of somatostatin receptor subtypes 2 and 5 (SSTR2 and SSTR5), leading to the inhibition of hormone secretion and tumor cell proliferation, as well as a reduction in circulating insulin-like growth factor-I (IGF-I) levels. This therapeutic approach is being investigated by the University of Naples Federico II in the SS-HCC pilot study.
- Brand names
- Sandostatin LARSomatuline DepotIpstylSomatuline Autogel
- Other names
- Octreotide-LAR + Lanreotide AutogelSS-HCC
02
Targets
SSTR3 (Somatostatin receptor 3)SSTR5 (Somatostatin receptor 5)SSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on octreotide + lanreotide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on octreotide + lanreotide.